Selecting a treatment plan to deal with acute migraine attacks is like putting together a toolkit of possible therapies which can be individualized for each patient, one expert said.
Restarting a CGRP monoclonal antibody (mAb) after a gap in treatment may lower response rate, a new study suggests. However, switching to a different mAb may counter this effect.
A mindfulness-based treatment has shown multiple benefits in patients with chronic migraine and medication-overuse headaches, results of a new randomized trial show.